LB Pharmaceuticals, a schizophrenia biotech developing a new version of a decades-old medicine, has closed a $75 million Series C raise and it began a Phase II trial last month, a source familiar with the company confirmed to Endpoints News.
As Karuna Therapeutics wraps up its FDA approval request for what could be the first new type of schizophrenia drug in decades, another East Coast biotech is raising $75 million to test an adjusted version of a decades-old medicine for the disorder next year.
NEW YORK--(BUSINESS WIRE)--LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today that the full results of a PET study of LB-102 (a N methylated version of the well-known and highly effective antipsychotic amisulpride), its lead compound to treat schizophrenia, have been presented at the 60th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from December 5-8 in San Juan, Puerto Rico.
NEW YORK--(BUSINESS WIRE)--LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today that results of PET studies of its lead compound to treat schizophrenia, LB-102, have been presented at the European College of Neuropsychopharmacology (ECNP) 2021 conference, held in Lisbon, Portugal.
NEW YORK--(BUSINESS WIRE)--LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today that results of PET studies of its lead compound to treat schizophrenia, LB-102, have been presented at the European College of Neuropsychopharmacology (ECNP) 2021 conference, held in Lisbon, Portugal.
NEW YORK--(BUSINESS WIRE)--LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1b clinical trial (Clinical Trials Identifier NCT04588129). This clinical study is designed to evaluate the dopamine receptor occupancy of LB-102 in healthy subjects using positron emission tomography (PET).
NEW YORK--(BUSINESS WIRE)--LB Pharmaceuticals Inc, a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, today announced the closing of a $10.0 million convertible note offering through a private placement to existing and new investors. The notes are structured to convert into equity as part of the Company’s Series B financing. Proceeds from this convertible note financing will support continued clinical development of the Company’s lead asset, LB-102. A PET imaging study is planned for later this year and a First-in-Patient Phase 2 clinical trial evaluating the effectiveness of LB-102 in treating the symptoms of schizophrenia is planned for mid-2021.
LB Pharmaceuticals Inc, (“LB”, or the “Company”), a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, today announced the results of a Phase 1 clinical study of LB-102 (NCT04187560), a novel derivative of amisulpride designed to treat schizophrenia. Data from this study were presented at the 33rd annual meeting of the European College of Neuropsychopharmacology (ECNP), which is being held virtually. A copy of the Company’s poster can be viewed online at http://lbpharma.us/presentations/